% | $
Quotes you view appear here for quick access.

CTI BioPharma Corp. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • nndung802000 nndung802000 Nov 14, 2012 1:00 PM Flag

    Presentation in London, stock up 8% in Milan today

    Pixuvri, CTICs lead therapeutic candidate has been sold in Europe.

    Pixuvri is the first approved treatment in the European Union in this patient setting. The decision cleared the way for CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway.

    The European market could generate up to $240 million in annual revenue, once the company is able to penetrate the market, and successful use overseas could also bolster the company's prospects for US approval.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.330.00(+0.18%)3:00 PMEDT